Literature DB >> 1372163

Administration of alpha 1-proteinase inhibitor ameliorates bleomycin-induced pulmonary fibrosis in hamsters.

A Nagai1, K Aoshiba, Y Ishihara, H Inano, K Sakamoto, E Yamaguchi, J Kagawa, T Takizawa.   

Abstract

The effect of alpha 1-proteinase inhibitor (alpha 1Pi) administration on the acute lung injury and subsequent fibrosis induced by bleomycin (BLM) was examined in hamsters. Pulmonary lesions were quantitatively reduced in alpha 1Pi-administered BLM-treated (BLM-alpha 1Pi) animals compared with animals treated by BLM alone (BLM-control) at both 7 days (acute stage) and 30 days (fibrotic stage) after BLM treatment. Analysis of intraalveolar cells from bronchoalveolar lavage (BAL) fluid revealed that neutrophils and lymphocytes were significantly decreased in the BLM-alpha 1Pi animals at 7 days after BLM treatment and that 30 days after BLM treatment macrophages as well as neutrophils and lymphocytes were remarkably decreased in the BLM-alpha 1Pi animals. The elastase activity in supernatants of BAL fluid during 7 days following BLM treatment was detected, but there was no difference between the two groups. In vitro studies on neutrophil responsiveness to stimulation of BAL fluid at 3 days after BLM treatment revealed noticeable chemotaxis and generation of superoxide anion of isolated neutrophils, but alpha 1Pi did not show any inhibitory effects on neutrophil responsiveness. We suggest that alpha 1Pi administration ameliorates pulmonary fibrosis preceded by acute lung injury induced by BLM treatment in hamsters and that the inhibitory effects of alpha 1Pi on lung injury may not be brought about by altered elastase activity, chemotaxis, or superoxide generation in neutrophils. Alternative mechanisms are discussed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1372163     DOI: 10.1164/ajrccm/145.3.651

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  14 in total

1.  Effects of erdosteine on bleomycin-induced lung fibrosis in rats.

Authors:  Haşim Boyaci; Hale Maral; Gupse Turan; Ilknur Başyiğit; Meltem O Dillioğlugil; Füsun Yildiz; Melih Tugay; Ayşe Pala; Cengiz Erçin
Journal:  Mol Cell Biochem       Date:  2006-01       Impact factor: 3.396

Review 2.  Acute exacerbation of idiopathic pulmonary fibrosis-a review of current and novel pharmacotherapies.

Authors:  Maya M Juarez; Andrew L Chan; Andrew G Norris; Brian M Morrissey; Timothy E Albertson
Journal:  J Thorac Dis       Date:  2015-03       Impact factor: 2.895

Review 3.  New strategies for treatment of pulmonary fibrosis.

Authors:  S H Phan
Journal:  Thorax       Date:  1995-04       Impact factor: 9.139

4.  Effects of alpha 1-antitrypsin on endotoxin-induced lung inflammation in vivo.

Authors:  Devipriya Subramaniyam; Chad Steele; Thomas Köhnlein; Tobias Welte; Olof Grip; Sadis Matalon; Sabina Janciauskiene
Journal:  Inflamm Res       Date:  2010-03-18       Impact factor: 4.575

Review 5.  Oxidative stress in pulmonary fibrosis: a possible role for redox modulatory therapy.

Authors:  Vuokko L Kinnula; Cheryl L Fattman; Roderick J Tan; Tim D Oury
Journal:  Am J Respir Crit Care Med       Date:  2005-05-13       Impact factor: 21.405

6.  Pathological versus protective functions of IL-22 in airway inflammation are regulated by IL-17A.

Authors:  Gregory F Sonnenberg; Meera G Nair; Thomas J Kirn; Colby Zaph; Lynette A Fouser; David Artis
Journal:  J Exp Med       Date:  2010-05-24       Impact factor: 14.307

7.  Escape from the matrix: multiple mechanisms for fibroblast activation in pulmonary fibrosis.

Authors:  Geoffrey J Laurent; Robin J McAnulty; Michael Hill; Rachel Chambers
Journal:  Proc Am Thorac Soc       Date:  2008-04-15

8.  Preventive effect of erythromycin on experimental bleomycin-induced acute lung injury in rats.

Authors:  A Azuma; T Furuta; T Enomoto; Y Hashimoto; K Uematsu; N Nukariya; A Murata; S Kudoh
Journal:  Thorax       Date:  1998-03       Impact factor: 9.139

Review 9.  The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis?

Authors:  Antje Moeller; Kjetil Ask; David Warburton; Jack Gauldie; Martin Kolb
Journal:  Int J Biochem Cell Biol       Date:  2007-08-30       Impact factor: 5.085

10.  Relative α₁-anti-trypsin deficiency in systemic sclerosis.

Authors:  Theresa C Barnes; Andy Cross; Marina E Anderson; Steven W Edwards; Robert J Moots
Journal:  Rheumatology (Oxford)       Date:  2011-03-30       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.